Tilmann Bochtler
Heidelberg, BW, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 64 publications
Molecularly Guided Therapy Versus Continued Chemotherapy in Unfavorable Cancer of Unknown Primary: Updated Efficacy and Safety From the Randomized, Phase II CUPISCO Study.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: September 03, 2026
68Ga-FAPI-PET/CT in extra-cervical CUP: Head-to-Head Comparison of 68Ga-FAPI-46 with 18F-FDG in 13 patients.
Journal: European journal of nuclear medicine and molecular imaging
Published: March 17, 2026
Neoadjuvant Atezolizumab and Chemotherapy for Non-Squamous Non-Small Cell Lung Cancer: Efficacy and Safety Results of an Open-Label, Single-Arm, Phase II Trial.
Journal: International journal of cancer
Published: January 17, 2026
Etiology of TP53 mutated complex karyotype acute myeloid leukemia.
Journal: Leukemia
Published: August 07, 2025
Rethinking cancer of unknown primary: from diagnostic challenge to targeted treatment.
Journal: Nature reviews. Clinical oncology
Published: July 10, 2025
Molecularly guided therapy versus chemotherapy after disease control in unfavourable cancer of unknown primary (CUPISCO): an open-label, randomised, phase 2 study.
Journal: Lancet (London, England)
Published: December 21, 2023
Management of a Pregnant ALK-Positive Lung Cancer Patient With Alectinib-Induced Pneumonitis and Bilateral Globus Pallidus Necrosis Postpartum.
Journal: Clinical lung cancer
Published: June 18, 2023
Frequency and Prognostic Value of Circulating Tumor Cells in Cancer of Unknown Primary.
Journal: Clinical chemistry
Published: June 01, 2023
Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary: a phase II trial.
Journal: Nature communications
Published: April 05, 2023
Last Updated: 09/26/2026